Determinación de la susceptibilidad a drogas de primera línea en aislamientos de Mycobacterium Tuberculosis por la técnica del tubo indicador de crecimiento micobacteriano
Determining the susceptibility to first-line drugs in M. tuberculosis isolates using the mycobacteria growth indicator tube method
Keywords:
tuberculosis, MGIT, resistencia bacteriana a drogas, susceptibilidad. (es)tuberculosis, MGIT, drug resistance, susceptibility. (en)
Downloads
Objetivo. Determinación de la susceptibilidad a drogas antituberculosas de primera línea en aislamientos de M. tuberculosis utilizando el método del tubo indicador de crecimiento micobacteriano (MGIT).
Material y métodos. Se estudiaron 49 aislamientos de M. tuberculosis procedentes del laboratorio de micobacteriología del departamento de Microbiología de la Universidad Nacional de Colombia. Se evaluó y comparó el método MGIT para la determinación de la resistencia o susceptibilidad a rifampicina, isoniacida, etambutol y estreptomicina con la prueba de oro, el método de las proporciones múltiples (PM).
Resultados. Por el método de las PM de los 49 aislamientos, 26 (53.0%) fueron sensibles a los cuatro antibióticos, 12 (24.5%) resistentes a un antibiótico y 11 (22.5%) a más de un antibiótico. Por el método MGIT de los 49 aislamientos, 31 (63.3%) fueron sensibles a los cuatro antibióticos, ocho (16.3%) resistentes a un antibiótico y 10 (20.6 %) resistentes a más de un antibiótico. Los porcentajes de concordancia observada oscilaron entre 83.7 y 97.9% y el índice kappa estuvo entre 0.61 y 0.83 para los diferentes antibióticos analizados. La sensibilidad del método MGIT a rifampicina, isoniacida, etambutol y estreptomicina fue de 88.9, 95.2, 62.5 y 58 por ciento respectivamente y la especificidad fue 97.7, 92.3, 98.8 y 98.4 por ciento respectivamente. Por el método MGIT se aislaron cepas resistentes de M. tuberculosis en un tiempo promedio de 7.85 días.
Conclusiones. El método MGIT permite la obtención de resultados confiables principalmente a isoniacida y rifampicina que son los antibióticos que determinan la multirresistencia del M. tuberculosis y en menor medida para estreptomicina y etambutol.
Objective. To evaluate the susceptibility of M. tuberculosis isolates to anti-tuberculosis first line drugs by Mycobacterium growth indicator tube method (MGIT).
Materials and methods. Forty-nine isolates of M. tuberculosis were tested, coming from the Mycobacteriology Laboratory of Microbiology Department of the Universidad Nacional de Colombia. The MGIT method was evaluated and compared in order to determine resistance or susceptibility to rifampicin, isoniazid, ethambutol and streptomycin with the gold standard method, the multiple proportion method (PM).
Results. With the PM method, of 49 isolates, 26 (53.0%) were sensitive to all four antibiotics, 12 (24.5%) were resistant to one antibiotic and 11 (22.5%) to more than one antibiotic. Using the MGIT method, of 49 isolates, 31 (63.3%) were sensitive to all four antibiotics, 8 (16.3%) were resistant to one antibiotic and 10 (20.6%) were resistant to more than one antibiotic. The concordance percentages observed oscillated between 83.7% and 97.9% and the kappa index was between 0.61 and 0.83 for the different antibiotics analyzed. The sensitivity of the MGIT method to the rifampicin, isoniazid, ethambutol and streptomycin was of 88.9, 95.2, 62.5 and 58% respectively and specifity was of 97.7, 92.3, 98.8 y 98.4% respectively. Using the MGIT method, isolates resistant to M. tuberculosis were determined in an average time of 7.85 days.
Conclusions. The MGIT method permits obtaining reliable results in less time than conventional methods with isoniazid and rifampicin which are the antibiotics that determine the multi-resistance of M tuberculosis and to a lesser degree to streptomycin and ethambutol.
References
Daniel TM. The history of tuberculosis. Respiratory Medicine (2006), doi:10.1016/j.rmed.2006.08.006.
Cave AJE. The evidence for the incidence of tuberculosis in ancient Egypt. Br. J Tubercl. 1939;33:142 -52.
Global Tuberculosis Control: Surveillance, Planning, Financing. WHO report 2006. Geneva, World Health Organization. (WHO/HTM/TB2006.362).
Espinal MA, The global situation of MDR-TB. Tuberculosis. 2003;83:44-51.
Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs – worldwide, MMWR Morb Mortal Wkly Rep. 2006;55:301-305.
Migliori GB, Loddenkemper R, Blasi F, Raviglione MC. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is «science» enough to tackle the epidemic? Eur Respir. J. 2007;29:423-427.
Raviglione MC, Espinal MA. Towards optimization of surveillance resistence to antituberculosis drug resistance. Eurosurveilance Monthly 2000;10:103-104
Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reiniero A. Global trends in resistance to antituberculosis drugs. N Engl J Med. 2001;344: 1294-1303.
León CI, Sierra CR, Naranjo ON, Garzón MC, Guerrero MI. Segundo estudio nacional de resistencia primaria del Mycobacterium tuberculosis a las drogas.INFECTIO.2002;6:83.
Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva, World Health Organization (WHO/HTM/TB2006.361
Canetti G, Froman F, Grosset J, Hauduroy P, Langerova M, Meisser G, Mitchison DA, Sula L. Mycobacteria: Laboratory methods for testing drug sensitivity and resistance. Bull WHO. 1963;29;565-578.
Palomino JC. Newer diagnostics for tuberculosis and multi-drug resistant tuberculosis. Curr Opin Pulm Med 2006;12:172-178.
Robledo JR, Mejia GI. Actualidad en el diagnóstico de la tuberculosis por el laboratorio. INFECTIO. 2001;5:251-258.
Becton Dickinson Microbiology Systems. BACTEC MGIT 960 System product and procedure manual. USA, 2001.
Echeverry J, Ardila E. Pruebas diagnósticas y proceso diagnóstico. En: Estrategias de Investigación en medicina clínica. Bogotá: Editorial Manual Moderno. 2001.
Altman DG. Inter-rater agreement. In Practical Statistics for Medical Research, London, Chapman & Hall/CRC. 1999: 403-409.
Pagano M, Gauvreau K. Principles of Biostatistics. Contingency tables. Editorial Duxbury Press, California. 1993: 311-337.
Walters SB, Hanna B.A. Testing of Susceptibility of Mycobacterium tuberculosis to Isoniazid and Rifampicin by Mycobacterium Growth Indicator Tube Method. J Clin Microbiol. 1996;34:1565-1567.
Rusch-Gerdes S, Domehl C, Nardi G, Gismondo MR, Welscher HM, Pfyffer G. Multicenter Evaluation of the Mycobacteria Growth Indicador Tube for Testing Susceptibility of Mycobacterium tuberculosis to First. Line Drugs. J Clin Microbiol. 1999;37:45-48.
Bergmann J, Fish G, Woods G. Evaluation of the BBL MGIT (Mycobacterial Growth Indicador Tube) AST SIRE System for Antimycobacterial Susceptibility Testing of Mycobacterium tuberculosis to 4 Primary Antituberculous Drugs. Arch Pathol Lab Med. 2000;124:82-86.
Goloubeva V, Lecocq M, Lassowsky P, Matthys F, Portaels F, Bastian I. Evaluation of Mycobacteria Grow Indicator Tube for direct and indirect drug susceptibility testing of Mycobacterium tuberculosis from respiratory specimens in a Siberian prison hospital. J Clin Microbiol. 2001;39:1501-150
Bemer P, Palicova F, Rusch-Gerdes S, Drugeon HB, Pfyffer G. Multicenter Evaluation of Fully Automates BACTEC Mycobacteria Growth Indicador Tube 960 System for Susceptibility Testing of. Mycobacterium tuberculosis. J Clin Microbiol. 2002;40:150-154.
Piffardi S, Luna A, Sakurada A, Lepe R. Evaluación comparativa del método automatizado BACTER MGIT con el método de las proporciones para determinar susceptibilidad a drogas antituberculosas en Chile. Rev Chil Enf Respir. 2004;20:139-143.
Koskela KA, Katila ML. Susceptibility Testing with the Manual Mycobacteria Growth Indicator Tube (MGIT) and the MGIT 960 System Provides Rapid and Reliable Verification of Multidrug-Resistant Tuberculosis. J Clin Microbiol. 2003;41(3):1235-1239.
Mengatto L, Chiani Y,Imaz MS. Evaluation of rapid alternative method for drug susceptibility testing in clinical isolates of Mycobacterium Tuberculosis. Mem Inst Oswualdo Cruz, Rio de Janeiro. 2006; 10: 535-542.
Piersimoni C, Nista D, Bornigia S, De Sio G. Evaluation of a New Method for Rapid Drug Susceptibility Testing of Mycobacteruim avium Complex Isolates by Using the Mycobacteria Growth Indicator tube. J Clin Microbiol. 1998;3:64-67.
Bergmann J, Woods G. Reliability of Mycobacteria Growth Indicador Tube for Testing Susceptibility of Mycobacterium tuberculosis to Ethambutol y Streptomycin. J Clin Microbiol. 1997;35:3325-3327.
Article abstract page views
Downloads
How to Cite
License
Copyright (c) 2008 Revista de la Facultad de Medicina

This work is licensed under a Creative Commons Attribution 3.0 Unported License.
-








